FORMULATION AND EVALUATION OF BILAYER SUSTAINED RELEASE TABLET OF ZOLPIDEM TARTRATE

Rabinarayan Parhi; Sanjay Kumar Bhupati; Padilam Suresh; Vijay Kumar

doi:10.14499/indonesianjpharm0iss0pp289-298

FORMULATION AND EVALUATION OF BILAYER SUSTAINED RELEASE TABLET OF ZOLPIDEM TARTRATE

Rabinarayan Parhi, Sanjay Kumar Bhupati, Padilam Suresh, Vijay Kumar

Abstract

The purpose of the present study was to develop a bilayer tablet of zolpidem tartrate (ZT) using sodium starch glycolate (SSG) as superdisintegrant in the immediate release (IR) layer and hydrophilic polymers such as hydroxypropyl methylcellulose (HPMC K4M), metalose 90 SH 4000, carbapol 974 PNF in sustained release (SR) layer. Both the IR and SR granules of ZT were evaluated for bulk density, tapped density, angle of repose, Carr’s index, Hausner ratio and loss on drying. All the values were found to be satisfactoy. The prepared bilayer tablets were evaluated for weight variation, hardness, friability, drug content, in vitro drug release, FT-IR studies, similarity factor and stability studies. In vitro dissolution studies were carried out in a USP dissolution apparatus I using 500mL of 0.01N HCl as dissolution medium. The formulations gave an initial burst effect to provide the loading dose of the drug followed by sustained release for 4 h. The data obtained were fitted to Zero order, First order, Higuchi’s model and Korsmeyer-Peppas equations. The release exponent (n) values for all the formulations were less than 0.45 indicating Fickian diffusion was the drug release mechanism. FT-IR studies indicated that there are no drug-excipient interactions. The similarity factor (f2) was calculated by comparing dissolution data of all the formulations with that of marketed bilayer tablet of ZT (Ambien CR). The f2 value was highest (70) for the formulation SF8 and was selected as promising formulation among all the developed formulations. The stability study was performed on the formulation SF8 at 25oC/60% RH, 30oC/75% RH and 40oC/75% RH (accelerated condition) for 3 months. The results indicated that there were no significant changes in aforesaid tablet properties.
Key words: bilayer tablets, zolpidem tartrate, sustained release, higuchi’s equation, similarity factor

Full Text:

Untitled

References

Abraham MA., Shirwaikar A. 1997. Formulation of multilayerd sustained release tablets using insoluble matrix system. Ind. J. Pharma Sci. 59: 312-315

Albertini B., Passerini N., Sabatino MD., Vitali B., Brigidi P., Rodriguez L. 2009. Polymer-lipid based mucoadhesive microspheres prepared by spraycongealing for the vaginal delivery of econazole nitrate. Eur. J. Pharm. Sci. 36:591–601

Al-Saidan SM., Krishnaiah YSR., Satyanarayana V., Bhaskar P., Karthikeyan RS. 2004. Pharmacokinetic evaluation of guar gumbased three-layer matrix tablets for oral controlled delivery of highly soluble metoprolol tartrate as a model drug. Eur.J. Pharm. Biopharm. 58: 697–703.

Drover DR. 2004. Comparative pharmacokinetics and pharmacodynamics of shortacting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin. Pharmacokinet. 43: 227−238.

Ebert B., Wafford KA., Deacon S. 2006. Treating insomnia: Current and investigational pharmacological approaches. Pharmacology & Therapeutics. 112: 612–629.

Goto T., Tanidab N. 2004. Pharmaceutical design of a novel colon-targeted delivery system using two-layer-coated tablets of three different pharmaceutical formulations, supported by clinical evidence in humans. J. Control. Release. 97: 31– 42.

Krystal AD. 2009. A compendium of placebocontrolled trials of the risks/benefits of pharmacological treatments for insomnia: The empirical basis for U.S. clinical practice. Sleep Med. Reviews. 13: 265–274.

Kumar BV., Prasad G., Ganesh B., Swathi C., Rashmi A., Reddy GA. 2010. Development and Evaluation of Guaifenesin Bilayer Tablet. Int. J. Pharm. Sci. Nanotech. 3: 1122-1128.

Martin A., Bustamante P., Chun A. 2002. Micromeritics, in Physical Pharmacy- Physical Chemical Principles in thePharmaceutical Sciences, 4th ed., Lippincott Williams and Wilkins, Baltimore. pp. 446–448.

Mendelson WB., Roth T., Cassella J., Roehrs T., Walsh JK., Woods JH., Buysse DJ., Meyer RE. 2004. The treatment of chronic insomnia: drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation Unit meeting symposium. Sleep Med. Rev. 8: 7−17.

Moen MD., and Plosker G.L. 2006. Zolpidem Extended-Release. Adis drug profile. CNS Drugs. 20: 419-426.

Mutalik S., Naha A., Usha AN., Ranjith AK., Musmade P., Manoj K., Anju P., Prasanna S. 2007. Preparation, In vitro, Preclinical and Clinical Evaluations of Once Daily Sustained Release Tablets of Aceclofenac. Arch Pharm. Res. 30: 222-234.

National Institutes of Health. National Institutes of Health state of the science conference statement: manifestations and management of chronic insomnia in adults. Sleep. 2005; 28: 1049-57.

Patra CN., Kumar AB., Pandit HK., Singh SP., Devi MV. 2007. Design and evaluation of sustained release bilayer tablets of propranolol hydrochloride. Acta Pharm. 57: 479–489.

Puia G. 2001. Glial-neuronal interactions: a crescendo in the degree of CNS complexity. Trends Pharmacol. Sci. 22: 498−499.

Rahman Z., Ali M., Khar RK. 2006. Design and evaluation of bilayer floating tablets of captopril. Acta Pharm. 56: 49-57.

Ramesh., Kumar DS., Guruviah., Harani A. 2010. Formulation and evaluation of the Bilayered sustained release matrix tablets of Metformin HCl Sr and Pioglitazone. American-Eurasian J. Scientific Res. 5: 176-182.

Reddy S., Kumar PP., Rajanarayana K., Rao YM. 2010. Formulation and Release Characteristic of a Bilayer Matrix Tablet Containing Glimepride Immediate Release Component and Metformin Hydrochloride as Sustained Release Component. Int. J. Pharm. Sci. Nanotech. 3: 851-859.

Rekhi GS., Nellore RV., Hussain AS., Tillman LG., Malinowski HJ., Augsburger LL. 1999. Identification of critical formulation and processing variables for metoprolol tartrate extended-release (ER) matrix tablets. J. Control. Release. 59:327–342.

Revision Bulletin Official. Zolpidem tartrate, The United States Pharmacopeial Convention, February 1, 2011. Sanna E., Busonero F., Talani G., Carta M., Massa F., Peis M., Maciocco E., Biggio G. 2002. Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA(A) receptor subtypes. Eur. J. Pharmacol. 451: 103−110.

Sateia MJ., Nowell PD. 2004. Insomnia. Lancet. 364: 1959−1973.

Seta Y., Higuchi F., Otsuka T., Nishimura K., Okada R., Koike H. 1988. Preparation and pharmacological evaluation of captopril sustained release dosage forms using oily semisolid matrix. Int. J. Pharm. 41: 255–262.

Siepmann J., Siepmann F. 2008. Mathematical modeling of drug delivery. Int. J. Pharm. 364: 328–343.

Staniforth J. 2002. Powder Flow, in Pharmaceutics-the Science of Dosage Form Design, 2nd ed. Ed. M. E.Aulton, Churchill Livingstone, London. pp. 207–208.

Swamy PV., Kinagi M.B., Biradar S.S., Gada S.N., Shilpa H. 2011. Formulation Design and Evaluation of Bilayer Buccal Tablets of Granisetron Hydrochloride. Ind. J. Pharm. Edu. Res. 45: 242-246.

Walsh JK. 2004. Clinical and socioeconomic correlates of insomnia. J. Clin. Psychiatry. 65 Suppl. 8:13-9.

Wu C-Y., Seville J.P.K. 2009. A comparative study of compaction properties of binar and bilayer tablets. Powder Tech. 189: 285–294

Ye Z-W, Rombout P., Remon J.P., Vervaet C., Mooter G.V. 2007. Correlation between the permeability of metoprolol tartrate through plasticized isolated ethylcellulose/hydroxypropyl methylcellulose films and drug release from reservoir pellets. Eur. J. Pharm. Biopharm. 67: 485–490.

Zhdanova IV. 2004. Advances in the management of insomnia. Expert Opin. Pharmacother. 5: 1573−1579.

DOI: http://dx.doi.org/10.14499/indonesianjpharm0iss0pp289-298